vs
Dominari Holdings Inc.（DOMH）与SCYNEXIS INC（SCYX）财务数据对比。点击上方公司名可切换其他公司
Dominari Holdings Inc.的季度营收约是SCYNEXIS INC的1.6倍（$30.1M vs $18.6M），SCYNEXIS INC净利率更高（65.7% vs -438.1%，领先503.9%），SCYNEXIS INC同比增速更快（1808.5% vs 220.4%），过去两年Dominari Holdings Inc.的营收复合增速更高（369.1% vs 268.5%）
SCYNEXIS是一家生物科技企业，专注于研发创新抗真菌疗法，用于治疗难治性真菌感染，满足未被覆盖的医疗需求，主要面向医院及专科护理市场，核心产品管线覆盖免疫低下患者等高危人群。
DOMH vs SCYX — 直观对比
营收规模更大
DOMH
是对方的1.6倍
$18.6M
营收增速更快
SCYX
高出1588.1%
220.4%
净利率更高
SCYX
高出503.9%
-438.1%
两年增速更快
DOMH
近两年复合增速
268.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.1M | $18.6M |
| 净利润 | $-131.8M | $12.3M |
| 毛利率 | — | — |
| 营业利润率 | -8.9% | 56.3% |
| 净利率 | -438.1% | 65.7% |
| 营收同比 | 220.4% | 1808.5% |
| 净利润同比 | -12426.2% | 376.5% |
| 每股收益（稀释后） | $-6.94 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOMHSCYX
| Q4 25 | $30.1M | $18.6M | ||
| Q3 25 | $50.8M | $334.0K | ||
| Q2 25 | $34.1M | $1.4M | ||
| Q1 25 | $8.1M | $257.0K | ||
| Q4 24 | $9.4M | $977.0K | ||
| Q3 24 | $4.0M | $660.0K | ||
| Q2 24 | $6.2M | $736.0K | ||
| Q1 24 | $1.4M | $1.4M |
净利润DOMHSCYX
| Q4 25 | $-131.8M | $12.3M | ||
| Q3 25 | $125.2M | $-8.6M | ||
| Q2 25 | $16.6M | $-6.9M | ||
| Q1 25 | $-32.5M | $-5.4M | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $-4.2M | $-2.8M | ||
| Q2 24 | $-6.1M | $-14.5M | ||
| Q1 24 | $-5.4M | $411.0K |
营业利润率DOMHSCYX
| Q4 25 | -8.9% | 56.3% | ||
| Q3 25 | -3.1% | -2516.5% | ||
| Q2 25 | -57.0% | -701.0% | ||
| Q1 25 | -394.6% | -3350.2% | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | -79.1% | -1563.6% | ||
| Q2 24 | -44.3% | -1255.0% | ||
| Q1 24 | -205.2% | -692.5% |
净利率DOMHSCYX
| Q4 25 | -438.1% | 65.7% | ||
| Q3 25 | 246.4% | -2572.2% | ||
| Q2 25 | 48.7% | -504.8% | ||
| Q1 25 | -400.5% | -2097.7% | ||
| Q4 24 | 11.4% | — | ||
| Q3 24 | -104.2% | -425.5% | ||
| Q2 24 | -99.1% | -1964.4% | ||
| Q1 24 | -398.0% | 29.9% |
每股收益（稀释后）DOMHSCYX
| Q4 25 | $-6.94 | $0.25 | ||
| Q3 25 | $7.27 | $-0.17 | ||
| Q2 25 | $1.12 | $-0.14 | ||
| Q1 25 | $-3.02 | $-0.11 | ||
| Q4 24 | $0.21 | — | ||
| Q3 24 | $-0.67 | $-0.06 | ||
| Q2 24 | $-1.01 | $-0.30 | ||
| Q1 24 | $-0.91 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.5M | $40.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $69.4M | $49.4M |
| 总资产 | $112.9M | $59.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DOMHSCYX
| Q4 25 | $80.5M | $40.0M | ||
| Q3 25 | $176.2M | $37.9M | ||
| Q2 25 | $28.2M | $44.8M | ||
| Q1 25 | $18.9M | $40.6M | ||
| Q4 24 | $8.2M | $59.3M | ||
| Q3 24 | $7.2M | $68.8M | ||
| Q2 24 | $12.1M | $73.0M | ||
| Q1 24 | $7.1M | $80.2M |
股东权益DOMHSCYX
| Q4 25 | $69.4M | $49.4M | ||
| Q3 25 | $210.2M | $36.4M | ||
| Q2 25 | $88.6M | $44.5M | ||
| Q1 25 | $42.4M | $50.5M | ||
| Q4 24 | $39.9M | $55.1M | ||
| Q3 24 | $38.3M | $58.5M | ||
| Q2 24 | $42.4M | $60.4M | ||
| Q1 24 | $47.7M | $74.1M |
总资产DOMHSCYX
| Q4 25 | $112.9M | $59.0M | ||
| Q3 25 | $223.4M | $51.1M | ||
| Q2 25 | $109.3M | $60.7M | ||
| Q1 25 | $52.3M | $67.9M | ||
| Q4 24 | $47.1M | $90.6M | ||
| Q3 24 | $43.4M | $99.0M | ||
| Q2 24 | $49.1M | $107.8M | ||
| Q1 24 | $52.2M | $118.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $22.7M | $18.4M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 1.50× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DOMHSCYX
| Q4 25 | $22.7M | $18.4M | ||
| Q3 25 | $-4.9M | $-8.7M | ||
| Q2 25 | $-353.0K | $-7.5M | ||
| Q1 25 | $1.2M | $-7.5M | ||
| Q4 24 | $-16.7M | $-24.0M | ||
| Q3 24 | $-4.7M | $765.0K | ||
| Q2 24 | $1.4M | $-10.9M | ||
| Q1 24 | $-8.6M | $-4.0M |
现金转化率DOMHSCYX
| Q4 25 | — | 1.50× | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
